These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38162177)

  • 1. Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study.
    Sato Y; Fujiwara S; Hata A; Kida Y; Masuda T; Amimoto H; Matsumoto H; Miyoshi K; Otsuka K; Tomii K
    JTO Clin Res Rep; 2023 Dec; 4(12):100608. PubMed ID: 38162177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
    Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
    Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
    Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
    Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies.
    Les I; Martínez M; Narro A; Pérez I; Sánchez C; Puntí L; Anaut P; Eguiluz S; Herrera A; Domínguez S
    Ann Med; 2021 Dec; 53(1):762-769. PubMed ID: 34060971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study.
    Les I; Pérez-Francisco I; Cabero M; Sánchez C; Hidalgo M; Teijeira L; Arrazubi V; Domínguez S; Anaut P; Eguiluz S; Elejalde I; Herrera A; Martínez M
    Front Pharmacol; 2022; 13():894550. PubMed ID: 35721217
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
    Tang H; Geng R; Xu X; Wang Y; Zhou J; Zhang S; Zhao L; Guan M; Bai C
    Front Immunol; 2022; 13():893179. PubMed ID: 35651612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
    Ghosh N; Chan KK; Jivanelli B; Bass AR
    J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between immune-related adverse events and treatment effectiveness in extensive disease small cell lung cancer.
    Yokoo K; Kitamura Y; Suzuki K; Morikawa K; Sawai T; Honda H; Kudo S; Yamada G
    Thorac Cancer; 2023 Aug; 14(23):2251-2258. PubMed ID: 37365145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
    Shams'ili S; Grefkens J; de Leeuw B; van den Bent M; Hooijkaas H; van der Holt B; Vecht C; Sillevis Smitt P
    Brain; 2003 Jun; 126(Pt 6):1409-18. PubMed ID: 12764061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study.
    Onodera R; Chiba S; Nihei S; Fujimura I; Akiyama M; Utsumi Y; Nagashima H; Kudo K; Maemondo M
    J Thorac Dis; 2023 Aug; 15(8):4237-4247. PubMed ID: 37691668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
    Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
    Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
    Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
    Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
    Wang L; Lou H; Li B; Li J; Yang YM
    Invest New Drugs; 2022 Feb; 40(1):151-156. PubMed ID: 34287773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
    Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC.
    Ricciuti B; Naqash AR; Naidoo J; Sehgal K; Miller A; Kehl K; Venkatraman D; Sands J; Lamberti G; Recondo G; Zhang J; Macherla S; Baig S; Walker P; Rangachari D; Gainor JF; Costa DB; Rizvi N; Sholl LM; Nishino M; Henick B; Farago AF; Awad MM
    JTO Clin Res Rep; 2020 Nov; 1(4):100074. PubMed ID: 34589955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.